INTERVIEW: Nanobiotix’s nanoparticles bring big benefits to radiotherapy
This article was originally published in Clinica
Bells and whistles may sound nice but simplicity always wins hands down. Indeed, keeping it simple was how cancer nanotech firm Nanobiotix captured public investors’ interest to successfully raise €14.2 million ($18.5 million) when it floated on the EuroNext stock exchange last year. Not a bad outcome for an early clinical stage company amidst a sluggish medtech IPO market.